Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688141 | 1.00 | ENPP1 (0.53) | ENPP1HTR2CPARP1ATMKDM4E | |
| SCHEMBL13720327 | 0.83 | ENPP1 (0.55) | ENPP1PARP1ATMKDM4ENPSR1 | |
| SCHEMBL13721430 | 0.83 | PARP1 (0.53) | ENPP1PARP1ATMKDM4EMAPT | |
| SCHEMBL13720770 | 0.83 | HTR3A (0.53) | ENPP1PARP1ATMTSHRALDH1A1 | |
| SCHEMBL19951504 | 0.83 | TSHR (0.63) | ENPP1PARP1ATMMAPTNPSR1 | |
| SCHEMBL30417899 | 0.83 | TSHR (0.63) | ENPP1PARP1ATMMAPTNPSR1 | |
| SCHEMBL8274438 | 0.80 | ENPP1 (0.62) | ENPP1ATMKDM4ENPSR1HTR6 | |
| SCHEMBL29468202 | 0.80 | KDM4E (0.54) | HTR2CPARP1KDM4EMAPTHTR6 | |
| SCHEMBL1132419 | 0.80 | KDM4E (0.54) | HTR2CPARP1KDM4EMAPTHTR6 | |
| Hydrochloric Acid SCHEMBL5767318 | 0.79 | KDM4E (0.56) | HTR2CPARP1KDM4EMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| CN-113574171-A | Compositions and methods for treating cancer | IN8生物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | The Institute of Cancer Reseach | 2012-05-31 | — | — | US | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2305221-A1 | Dna damage repair inhibitors for treatment of cancer | Kudos Pharmaceuticals Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | ENPP1 1490/4885HTR2C 4452/4885PARP1 1/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | ENPP1 904/4885HTR2C 3159/4885PARP1 2/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | ENPP1 861/4885HTR2C 4289/4885PARP1 1/4885 |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | MRE11, ERCC4, PARP2 | ENPP1 260/4885HTR2C 4179/4885PARP1 7/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | ENPP1 234/4885HTR2C 4111/4885PARP1 3/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | ENPP1 276/4885HTR2C 4147/4885PARP1 4/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | ENPP1 1847/4885HTR2C 3185/4885PARP1 3/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | ENPP1 260/4885HTR2C 4179/4885PARP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.